Comprehensive Review Of Rheumatoid Arthritis: Insights, Challenges, And Prospects
Article Sidebar
Main Article Content
Abstract
This comprehensive review explores the multifaceted landscape of rheumatoid arthritis (RA), encompassing its epidemiology, pathophysiology, clinical manifestations, diagnosis, treatment approaches, and the impact on patients' quality of life. The review delves into the global prevalence of RA, demographic patterns, and associated risk factors, shedding light on the complex interplay of genetics, immunology, and environmental triggers in disease development. The pathophysiological mechanisms involving immunological dysregulation, genetic factors, and environmental triggers are elucidated, providing a foundation for understanding the intricate processes driving RA. Detailed insights into the clinical manifestations of RA, including joint involvement, extra-articular manifestations, and the progression of the disease, are provided. The diagnostic landscape is explored, covering the ACR/EULAR classification criteria, diagnostic imaging, and laboratory tests that facilitate accurate and timely identification of RA. Treatment approaches, from pharmacological therapies like DMARDs and biologics to non-pharmacological interventions such as physical and occupational therapy, emphasizing a holistic management strategy. The economic burden of RA, its impact on healthcare utilization, and the broader societal implications are scrutinized, providing valuable insights into the challenges faced by both individuals and healthcare systems. Prevention and disease management strategies are highlighted, emphasizing the importance of early intervention, patient education, and public health initiatives in mitigating the impact of RA. Current challenges in RA management are outlined, with proposed future research directions aimed at advancing understanding and treatment.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Conforti A, Di Cola I, Pavlych V, Ruscitti P, Berardicurti O, Ursini F, Giacomelli R, Cipriani P. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmunity reviews. 2021;20(2):102735.
Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD, Tanasescu R. Extra-articular manifestations in rheumatoid arthritis. Maedica. 2010;5(4):286.
Joseph A, Brasington R, Kahl L, Ranganathan P, Cheng TP, Atkinson J. Immunologic rheumatic disorders. Journal of Allergy and Clinical Immunology. 2010;125(2):S204-15.
Cho SK, Kim D, Won S, Lee J, Choi CB, Choe JY, Hong SJ, Jun JB, Kim TH, Koh E, Lee HS. Factors associated with time to diagnosis from symptom onset in patients with early rheumatoid arthritis. The Korean journal of internal medicine. 2019;34(4):910.
Initiative C. 2010 rheumatoid arthritis classification criteria. Arthritis & Rheumatism. 2010;62(9):2569-81.
Initiative C. 2010 rheumatoid arthritis classification criteria. Arthritis & Rheumatism. 2010 Sep;62(9):2569-81.
Ometto F, Botsios C, Raffeiner B, Sfriso P, Bernardi L, Todesco S, Doria A, Punzi L. Methods used to assess remission and low disease activity in rheumatoid arthritis. Autoimmunity reviews. 2010;9(3):161-4.
Smith E, Hoy DG, Cross M, Vos T, Naghavi M, Buchbinder R, Woolf AD, March L. The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study. Annals of the rheumatic diseases. 2014;73(8):1462-9.
Mankia K, Siddle HJ, Kerschbaumer A, Rodriguez DA, Catrina AI, Cañete JD, Cope AP, Daien CI, Deane KD, El Gabalawy H, Finckh A. EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. Annals of the Rheumatic Diseases. 2021;80(10):1286-98.
Zhang X, Li W, Zhang X, Zhang X, Jiang L, Guo Y, Wang X. Association between polymorphism in TRAF1/C5 gene and risk of rheumatoid arthritis: a meta-analysis. Molecular biology reports. 2014;41:317-24.
Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, Alpizar-Rodriguez D, Lauper K. Global epidemiology of rheumatoid arthritis. Nature Reviews Rheumatology. 2022;18(10):591-602.
Curran AM, Naik P, Giles JT, Darrah E. PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets. Nature Reviews Rheumatology. 2020;16(6):301-15.
Scherer HU, Häupl T, Burmester GR. The etiology of rheumatoid arthritis. Journal of autoimmunity. 2020;110:102400.
Damerau A, Gaber T. Modeling rheumatoid arthritis in vitro: From experimental feasibility to physiological proximity. International journal of molecular sciences. 2020;21(21):7916.
Van Drongelen V, Holoshitz J. Human leukocyte antigen–disease associations in rheumatoid arthritis. Rheumatic Disease Clinics. 2017;43(3):363-76.
Bizzaro N, Bartoloni E, Morozzi G, Manganelli S, Riccieri V, Sabatini P, Filippini M, Tampoia M, Afeltra A, Sebastiani G, Alpini C. Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. Arthritis research & therapy. 2013;15:1-9.
Yu HC, Lu MC. The roles of anti-citrullinated protein antibodies in the immunopathogenesis of rheumatoid arthritis. Tzu-Chi Medical Journal. 2019;31(1):5.
Alsaber A, Pan J, Al-Herz A, Alkandary DS, Al-Hurban A, Setiya P. Influence of ambient air pollution on rheumatoid arthritis disease activity score index. International journal of environmental research and public health. 2020;17(2):416.
Wasserman AM. Diagnosis and management of rheumatoid arthritis. American family physician. 2011;84(11):1245-52.
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. Jama. 2018;320(13):1360-72.
Salaffi F, Gutierrez M, Carotti M. Ultrasound versus conventional radiography in the assessment of bone erosions in rheumatoid arthritis. Clin Exp Rheumatol. 2014;32(1 Suppl 80):S85-90.
Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PloS one. 2015;10(2):e0117952.
Chen Y, Xu W, Yang H, Shao M, Xu S, Deng J, Gao X, Liu H, Shuai Z, Xu S, Pan F. Serum levels of hepcidin in rheumatoid arthritis and its correlation with disease activity and anemia: a meta-analysis. Immunological investigations. 2021;50(2-3):243-58.
Haddani F, Guich A, Youssoufi T, Boudhar E, Abouqal R, Achemlal L, Allali F, Bahiri R, Bouchti E, Maghraoui E, Ghozlani I. Comorbidities in rheumatoid arthritis: The RBSMR study. Int. J. Clin. Rheumtol. 2020;15:1-0.
Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. Cmaj. 2009;181(11):787-96.
De Germay S, Bagheri H, Despas F, Rousseau V, Montastruc F. Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study. Rheumatology. 2020;59(9):2360-7.
Mun S, Lee J, Park M, Shin J, Lim MK, Kang HG. Serum biomarker panel for the diagnosis of rheumatoid arthritis. Arthritis Research & Therapy. 2021;23:1-0.
Marotta A, Maksymowych WP. SAT0070 levels of 14-3-3eta predict good eular response to anti-TNF treatment in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2014;73:615.
Kgoebane K, Ally MM, Duim-Beytell MC, Suleman FE. The role of imaging in rheumatoid arthritis. SA journal of radiology. 2018;22(1):1-6.
Giles JT. Extra-articular manifestations and comorbidity in rheumatoid arthritis: Potential impact of pre–rheumatoid arthritis prevention. Clinical Therapeutics. 2019;41(7):1246-55.
Linares V, Alonso V, Domingo JL. Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity. Expert opinion on drug safety. 2011;10(2):253-63.